Eric Easom, AN2 Therapeutics CEO
March 7, 2022 10:42 AM EST
Financing

A lone biotech braves the bone-dry IPO fore­cast, seek­ing to go pub­lic amidst a bar­ren land­scape

Max Gelman

Senior Editor

Just two months af­ter putting to­geth­er a pri­vate fund­ing round, a Cal­i­for­nia biotech is head­ed to Nas­daq.

AN2 Ther­a­peu­tics filed its S-1 pa­per­work on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times